These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36919687)

  • 1. Tapentadol for the management of cancer pain in adults: an update.
    Boland JW
    Curr Opin Support Palliat Care; 2023 Jun; 17(2):90-97. PubMed ID: 36919687
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Undesired side effects of tapentadol in comparison to oxycodone. A meta-analysis of randomized controlled comparative studies].
    Merker M; Dinges G; Koch T; Kranke P; Morin AM
    Schmerz; 2012 Feb; 26(1):16-26. PubMed ID: 22366930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxycodone for cancer-related pain.
    Schmidt-Hansen M; Bennett MI; Arnold S; Bromham N; Hilgart JS
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD003870. PubMed ID: 28829910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does tapentadol affect sex hormone concentrations differently from morphine and oxycodone? An initial assessment and possible implications for opioid-induced androgen deficiency.
    Eichenbaum G; Göhler K; Etropolski M; Steigerwald I; Pergolizzi J; Kim M; Vorsanger G
    J Opioid Manag; 2015; 11(3):211-27. PubMed ID: 25985806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opioids for cancer pain - an overview of Cochrane reviews.
    Wiffen PJ; Wee B; Derry S; Bell RF; Moore RA
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD012592. PubMed ID: 28683172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.
    Frampton JE
    Drugs; 2010 Sep; 70(13):1719-43. PubMed ID: 20731478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
    Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
    Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
    Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
    Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
    Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
    Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.
    Haeseler G; Schaefers D; Prison N; Ahrens J; Liu X; Karch A
    BMC Anesthesiol; 2017 Jul; 17(1):91. PubMed ID: 28693439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tapentadol versus oxycodone analgesia and side effects after laparoscopic hysterectomy: A randomised controlled trial.
    Comelon M; Raeder J; Drægni T; Lieng M; Lenz H
    Eur J Anaesthesiol; 2021 Sep; 38(9):995-1002. PubMed ID: 33428347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes Associated with Treatment of Chronic Pain with Tapentadol Compared with Morphine and Oxycodone: A UK Primary Care Observational Study.
    Morgan CL; Jenkins-Jones S; Currie C; Baxter G
    Adv Ther; 2019 Jun; 36(6):1412-1425. PubMed ID: 30963513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution?
    Candiotti KA; Gitlin MC
    Curr Med Res Opin; 2010 Jul; 26(7):1677-84. PubMed ID: 20465361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients.
    Vorsanger G; Xiang J; Biondi D; Upmalis D; Delfgaauw J; Allard R; Moskovitz B
    Pain Res Manag; 2011; 16(4):245-51. PubMed ID: 22059194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study.
    Afilalo M; Etropolski MS; Kuperwasser B; Kelly K; Okamoto A; Van Hove I; Steup A; Lange B; Rauschkolb C; Haeussler J
    Clin Drug Investig; 2010; 30(8):489-505. PubMed ID: 20586515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
    Etropolski M; Kelly K; Okamoto A; Rauschkolb C
    Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study.
    Hale M; Upmalis D; Okamoto A; Lange C; Rauschkolb C
    Curr Med Res Opin; 2009 May; 25(5):1095-104. PubMed ID: 19301989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs.
    Obradovic M; Ikenberg R; Hertel N; Antoñanzas F; Gálvez R; Liedgens H
    Clin Ther; 2012 Apr; 34(4):926-43. PubMed ID: 22417717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
    Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
    J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans.
    Jeong ID; Camilleri M; Shin A; Iturrino J; Boldingh A; Busciglio I; Burton D; Ryks M; Rhoten D; Zinsmeister AR
    Aliment Pharmacol Ther; 2012 May; 35(9):1088-96. PubMed ID: 22348605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.